

Global Erythropoietin Drugs Demand in 2028 with A CAGR Of 5.7%

Growth of the market is driven by rise in number of treatment cycles for chemotherapy and increase in number cases including cancer, HIV, kidney diseases.

PORTLAND, OREGON, UNITED STATES, November 2, 2022 /EINPresswire.com/

-- Erythropoietin/hematopoietin is a glycoprotein hormone that triggers production of red blood cells in the bone marrow through erythropoiesis. Erythropoietin drug was developed with the objective to treat anemic conditions caused from ESRD treatments and dialysis procedures. EPO drugs have gained approvals for chemotherapy-induced anemia. Advanced application of recombinant DNA technology enables production of erythropoietin for in-vitro conditions/synthetic variants, which are referred to as recombinant human erythropoietin (rHuEPO). Currently, EPO's, are largely used in anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART).


The global [erythropoietin drugs market](#) size was valued at \$9,243.12 million in 2020, and is projected to reach \$14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.

For Right Perspective, Download Sample PDF at:

<https://www.alliedmarketresearch.com/request-sample/59>

Covid-19 scenario:

The outbreak of Covid-19 disrupted the workflow in the healthcare sector as the rapid spread of coronavirus forced several industries to shut down temporarily. However, the pandemic had a positive effect on the demand for medical services including erythropoietin.



As erythropoietin is used to treat anemia and can be effective against Covid-19, which boosted its demand. Moreover, it has anti-ischemic, anti-apoptotic, and regenerative effects in several tissues such as kidney, lungs, nervous system, retina, and pancreas. Thus, it can be used to treat critically ill patients.

Rise in prevalence of anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART). Hence, rise in number of treatment cycles for chemotherapy and increase in incidences of end stage renal diseases (dialysis) has increased demand for EPO. Side effects associated with EPO including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) restrain growth of the erythropoietin drugs market. In addition, rise in trends of commercialization for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and increase in level of awareness regarding benefits of EPO therapeutics boost growth of the erythropoietin drugs market.

Enquiry for Short-term and Long-term Impacts of COVID-19 at:

<https://www.alliedmarketresearch.com/purchase-enquiry/59>

Key Findings Of The Study

On the basis of product, the epoetin-alfa held largest share in the global erythropoietin drugs market in 2020.

On the basis of application, the kidney disorders held the largest erythropoietin drugs market share in 2020, and is expected to remain dominant throughout the forecast period.

By region, North America is expected to experience growth at the highest rate, during the forecast period.

[illegible]

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

On the basis of application, the kidney disorder segment dominated the market in 2020, contributing to more than two-fifths of the market. In addition, the segment is expected to manifest the highest CAGR of 6.5% during the forecast period.

Some of the Top Players in the Global Market Are:

The global erythropoietin drugs market includes an in-depth analysis of the prime market players such as Johnson & Johnson, Amgen Inc., Roche, Hospira Inc., Biocon, LG Life Sciences Ltd., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Ranbaxy Laboratories Ltd., and Celltrion, Inc.

Speak to our Analysts: <https://www.alliedmarketresearch.com/connect-to-analyst/59>

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: <https://www.alliedmarketresearch.com/avenue/trial/starter>

"We have also published few syndicated market studies in the similar area that might be of your interest.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Submit a press release

David Correa

Allied Analytics LLP

+1 503-894-6022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/599135783>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.